Skip to main content
. Author manuscript; available in PMC: 2012 Jun 9.
Published in final edited form as: Int J Neuropsychopharmacol. 2011 Jun 9;15(5):657–668. doi: 10.1017/S1461145711000848

Figure 3.

Figure 3

Effects of LY379268 on ketamine-induced elevations in gamma power and locomotor activity in rats. (A - insert) LY379268 potently and dose-dependently depressed ongoing gamma power by up to 60% during the 30 min pretreatment phase of the recordings, compared to vehicle treatment. (A) LY379268 significantly and completely reduced the rise in gamma power induced by ketamine (5mg/kg sc), compared with vehicle pretreatment. This effect was dose-dependent. (B) Pretreatment with LY379268 (0.3 – 3 mg/kg sc) induced a dose-dependent and complete suppression of ketamine (5 mg/kg sc) induced hyperlocomotor activity conmpared with vehicle pretreatment. Data represent mean ± S.E.M.; n=5. Open arrow indicates timing of LY379268 administration, and closed arrow indicates ketamine administration.